Home  »  Companies   »  Corbus Pharmaceuticals Holdings Inc. (CRBP) Reveal...

Corbus Pharmaceuticals Holdings Inc. (CRBP) Reveals an Earnings Mystery

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) went up by 6.48% from its latest closing price compared to the recent 1-year high of $0.93. The company’s stock price has collected -11.06% of loss in the last five trading sessions.

Is It Worth Investing in Corbus Pharmaceuticals Holdings Inc. (NASDAQ :CRBP) Right Now?

Plus, the 36-month beta value for CRBP is at 1.80. Opinions of the stock are interesting as 1 analysts out of 2 who provided ratings for Corbus Pharmaceuticals Holdings Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


The average price from analysts is $3.00, which is $2.88 above the current price. CRBP currently public float of 124.68M and currently shorts hold a 3.82% ratio of that float. Today, the average trading volume of CRBP was 2.47M shares.

CRBP’s Market Performance

CRBP stocks went down by -11.06% for the week, with a monthly drop of -5.74% and a quarterly performance of -46.86%, while its annual performance rate touched -86.93%. The volatility ratio for the week stands at 10.77% while the volatility levels for the past 30 days are set at 8.53% for Corbus Pharmaceuticals Holdings Inc. The simple moving average for the period of the last 20 days is -8.98% for CRBP stocks with a simple moving average of -57.97% for the last 200 days.

Analysts’ Opinion of CRBP

Many brokerage firms have already submitted their reports for CRBP stocks, with ROTH Capital repeating the rating for CRBP by listing it as a “Neutral.” The predicted price for CRBP in the upcoming period, according to ROTH Capital is $3 based on the research report published on September 08th of the previous year 2020.

Jefferies gave a rating of “Hold” to CRBP, setting the target price at $2.50 in the report published on September 08th of the previous year.

CRBP Trading at -20.49% from the 50-Day Moving Average

After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.57% of loss for the given period.

Volatility was left at 8.53%, however, over the last 30 days, the volatility rate increased by 10.77%, as shares sank -12.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.04% lower at present.

During the last 5 trading sessions, CRBP fell by -11.06%, which changed the moving average for the period of 200-days by -72.39% in comparison to the 20-day moving average, which settled at $0.1256. In addition, Corbus Pharmaceuticals Holdings Inc. saw -81.32% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CRBP starting from Millian Craig Stuart, who purchase 5,000 shares at the price of $0.25 back on Aug 10. After this action, Millian Craig Stuart now owns 27,000 shares of Corbus Pharmaceuticals Holdings Inc., valued at $1,272 using the latest closing price.

Moran Sean F., the Chief Financial Officer of Corbus Pharmaceuticals Holdings Inc., purchase 20,000 shares at $0.26 during a trade that took place back on Aug 10, which means that Moran Sean F. is holding 199,272 shares at $5,198 based on the most recent closing price.

Stock Fundamentals for CRBP

Current profitability levels for the company are sitting at:

  • -6350.09 for the present operating margin
  • -85.92 for the gross margin

The net margin for Corbus Pharmaceuticals Holdings Inc. stands at -5176.38. Equity return is now at value -75.30, with -46.50 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 5.89.